Grifols Q3 net profit rises 28% to EUR 162 million

• Grifols’ third-quarter 2026 net profit climbed 28% year-over-year to EUR 162 million.
• Revenue reached EUR 2.04 billion for the quarter, primarily driven by growth in Biopharma.
• At September’s end, net leverage declined year-over-year to 3.98x, while liquidity increased to EUR 2.14 billion.
• Egyptian operations remain on track to collect approximately one million liters of plasma in 2026.
• Full-year 2026 guidance remains unchanged following nine-month performance in line with expectations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grifols SA published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.